Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBITDA: 2020-2025

Historic EBITDA for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to -$2.6 million.

  • Burning Rock Biotech's EBITDA rose 61.44% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 million, marking a year-over-year increase of 76.70%. This contributed to the annual value of -$47.0 million for FY2024, which is 48.61% up from last year.
  • According to the latest figures from Q3 2025, Burning Rock Biotech's EBITDA is -$2.6 million, which was down 85.34% from -$1.4 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's EBITDA ranged from a high of -$1.4 million in Q2 2025 and a low of -$44.3 million during Q4 2021.
  • Its 3-year average for EBITDA is -$13.1 million, with a median of -$14.6 million in 2023.
  • As far as peak fluctuations go, Burning Rock Biotech's EBITDA crashed by 73.72% in 2022, and later surged by 90.35% in 2025.
  • Over the past 5 years, Burning Rock Biotech's EBITDA (MRQ) stood at -$44.3 million in 2021, then rose by 20.17% to -$35.3 million in 2022, then increased by 28.94% to -$25.1 million in 2023, then surged by 64.78% to -$8.8 million in 2024, then soared by 70.40% to -$2.6 million in 2025.
  • Its EBITDA was -$2.6 million in Q3 2025, compared to -$1.4 million in Q2 2025 and -$1.9 million in Q1 2025.